ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors with or without Prophylactic Treatment

Tammuella Chrisentery-Singleton, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Michael U Callaghan, Miguel Escobar, Adam Giermasz, M Nikki Hirsh, Janna Journeycake, Sonia Nasr, Doris V Quon, Mark Reding, Michael Recht
Thrombosis & Hemostasis Summit of North American 2022
August 17, 2022
Adult treatments, AHP including (AIP)

Can’t find what you’re looking for?
Please contact for assistance.